Efficacy and safety of early versus late titration of fixed-dose irbesartan/hydrochlorothiazide: ACTUAL study

References

• Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: Analysis of worldwide data. Lancet. 2005;365:217–223.
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. JAMA. 2010;303:2043–2050.
   PubMed Web of Science ®Google Scholar
• Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, . 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–1187.
   PubMed Web of Science ®Google Scholar
• Bobrie G, Delonca J, Moulin C, Giacomino A, Postel-Vinay N, Asmar R. A home blood pressure monitoring study comparing the antihypertensive efficacy of two angiotensin II receptor antagonist fixed combinations. Am J Hypertens. 2005;18:1482–1488.
   PubMed Web of Science ®Google Scholar
• Coca A, Calvo C, Sobrino J, Gomez E, Lopez-Paz JE, Sierra C, . Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther. 2003; 25:2849–2864.
   PubMed Web of Science ®Google Scholar
• Cushman WC, Neutel JM, Saunders E, Bakris GL, Ferdinand KC, Ofili EO, . Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol. 2008;17:27–36.
   PubMedGoogle Scholar
• Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, Ofili EO, . The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: The INCLUSIVE trial. J Clin Hypertens (Greenwich). 2005;7:578–586.
   PubMedGoogle Scholar
• Neutel JM, Smith D. Ambulatory blood pressure comparison of the anti-hypertensive efficacy of fixed combinations of irbesartan/hydrochlorothiazide and losartan/hydrochlorothiazide in patients with mild-to-moderate hypertension. J Int Med Res. 2005;33:620–631.
   PubMed Web of Science ®Google Scholar
• Ofili EO, Ferdinand KC, Saunders E, Neutel JM, Bakris GL, Cushman WC, . Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy. J Natl Med Assoc. 2006;98:618–626.
   PubMed Web of Science ®Google Scholar
• Saunders E, Cable G, Neutel J. Predictors of blood pressure response to angiotensin receptor blocker/diuretic combination therapy: A secondary analysis of the irbesartan/ hydrochlorothiazide blood pressure reductions in diverse patient populations (INCLUSIVE) study. J Clin Hypertens (Greenwich). 2008;10:27–33.
   PubMed Web of Science ®Google Scholar
• Sowers JR, Neutel JM, Saunders E, Bakris GL, Cushman WC, Ferdinand KC, . Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006;8:470–480.
   PubMedGoogle Scholar
• Sun NL, Jing S, Chen J. [The control rate of irbesartan/ hydrochlorothiazide combination regimen in the treatment of Chinese patients with mild to moderate hypertension]. Zhonghua Xin Xue Guan Bing Za Zhi. 2005;33:618–621.
   PubMedGoogle Scholar
• Flack JM, Yunis C, Preisser J, Holmes CB, Mensah G, McLean B, Saunders E. The rapidity of drug dose escalation influences blood pressure response and adverse effects burden in patients with hypertension: The Quinapril Titration Interval Management Evaluation (ATIME) Study. ATIME Research Group. Arch Intern Med. 2000;160:1842–1847.
   PubMed Web of Science ®Google Scholar
• Neldam S, Edwards C, Telmisartan/Hydrochlorothiazide I. Results of increasing doses of hydrochlorothiazide in combination with an angiotensin receptor blocker in patients with uncontrolled hypertension. J Clin Hypertens (Greenwich). 2008;10:612–618.
   PubMed Web of Science ®Google Scholar
• Kochar M, Guthrie R, Triscari J, Kassler-Taub K, Reeves RA. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999;12: 797–805.
   PubMed Web of Science ®Google Scholar
• Gradman AH, Brady WE, Gazdick LP, Lyle P, Zeldin RK. A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension. Clin Ther. 2002;24: 1049–1061.
   PubMed Web of Science ®Google Scholar
• Ruilope LM, Malacco E, Khder Y, Kandra A, Bonner G, Heintz D. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: The VAST study. Clin Ther. 2005; 27:578–587.
   PubMed Web of Science ®Google Scholar
• Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004; 363:2022–2031.
   PubMed Web of Science ®Google Scholar